Advertisement

Caprotec bioanalytics GmbH, a Berlin-based biotechnology company with a subsidiary in Burlington, said Monday that the European Patent Office has granted the last of three core patents for its capture compound mass spectrometry (CCMS) technology. 

The technology can be used to investigate small molecule and protein interactions in the human proteome by isolating and identifying selected proteins from a complex biological sample. The goal is to discover or confirm relevant protein drug targets, the mode of drug action and off-target proteins that may cause adverse side effects.

SOURCE

Advertisement
Advertisement